LRI+Vocab+WG+Meeting+2011-6-21

include component="page" wikiName="siframework" page="LRI Header" =LRI Vocab Meeting Minutes=
 * Date:** 06/21/2011
 * Time:** 10:00AM – 11: 00AM EDT
 * Dial in:** 1-408-600-3600 **| Pass-code: **660 071 157

Review Consensus Statement  and discuss progress made at F2F meeting.
 * Meeting Agenda:**
 * 1) In-Scope Test list

Attendance
Tom Boal, Neelima Chennamaraja, Freida Hall, Rob Hausam, Cindy Johns, Jingdong Li, Cheryl Liu, Diana Massey, Natalie Menser, Riki Merrick, Bill Ormerod, Jennifer Sisto,Virginia Sturmfels, Merideth Vida, and Bob Yencha.

Action Items
Cindy Johns || Completed || 6/22/11 ||
 * **#** || **Date Initiated** || **Action** || **Owner** || **Status** || **Date Closed** ||
 * 1 || 06/20/11 || Include section 13.2 of the Final Approved Use Case on the LRI Strategy & Consensus Statement Page || Merideth Vida
 * 2 || 06/15/11 || Members to review In-Scope Test List
 * Need to resolve question mark in table regarding A3- Format || All Members || In Progress ||  ||
 * 3 || 06/15/11 || Take an in-depth look at information that was transposed under the Position and Strategy for use of SNOMED and review the Position & Stategy for UCUM || All Members || In Progress ||  ||
 * 4 || 06/15/11 || Request of any group member to provide examples/samples of Cystic Fibrosis data types that fall under genomics, in relation to SNOMED || Participant from the Group || - ||  ||
 * 5 || 06/21/11 || Incorporate HL7 requirements into the consensus document and build out a table by Thursday so it can be looked at next Tuesday; this is not due officially until June 30, 2011. || Riki Merrick & Bill Ormerod || In Progress ||  ||
 * 6 || 06/21/11 || Follow up with Jim Case on pending questions on SNOMED || Riki Merrick || In Progress ||  ||
 * 7 || 06/21/11 || On the Position and Strategy for UCUM: * Comment on third from last bullet- group not sure what it means- request for someone to articulate this bullet a little more (referencing Canonical Names) || Request a member of the group to sign up || Removed from document || 6/24/11 ||
 * 8 || 6/21/11 || Review overall Strategy and Consensus Statement & Position and Strategy for Use of UCUM and make sure that content is being captured accurately || All Members || In Progress ||  ||
 * 9 || 6/21/11 || Follow up with Dr. James Harrison regarding the concerns he raised at the F2F meeting on anatomic pathology and lipid risk assessment tests during the In-Scope Test list discussion. || Cindy Johns || In Progress ||  ||
 * 10 || 6/15/11 || Determine if SNOMED Qualifier hierarchy is the appropriate one to use for presence and absencing findings || Rob Hausen || In Progress ||  ||
 * 11 || 6/15/11 || Verify regulatory requirement for exact match of reported test name communicated from sender with what the receiver displays (in reference to using SNOMED for CWE.9 in SPM.4). || Virginia Sturmfels || In Progress ||  ||

Meeting Notes

 * The purpose of the meeting was to make sure that everyone is in agreement regarding the Consensus Statement <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">and In-Scope Test List; we also have some questions to answer and would like to get through as much as possible.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">The Consensus Statement can be found on the Wiki by searching “LRI Consensus.”


 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">LRI Strategy & Consensus Statement Review **
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Ultimate goal: Standardized or structured data to be used as the format of relaying these results.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">From a vocabulary process standpoint, we need names and processes squared away. We need some cross-mapping.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Merideth Vida: Looks like the format we are looking for is mostly the standardized structure data; Looking back at Use-Case, looks like Formats 1,2, and 3, will be used in exchanging data;
 * **__<span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Achieved agreement on incorporating our documents into the consensus statement rather than maintaining them separately. __**
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Frieda Hall: it will be good to have everything in one document; it will be easier to manage, especially when it comes to the process of consensus.
 * **<span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">In Scope Test Review: http://wiki.siframework.org/In-Scope+Test+Review **
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">The team went through the <span style="font-family: 'Arial','sans-serif'; font-size: 13px;">Recommended In-Scope Test List for LRI Pilot and Testing of LOINC Vocabulary <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">and decided on select Targeted Formats A1, A2, or A3 for the Test Long Name. This was done following these report format definitions:
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">A1 Tests and/or components with numeric results, units, and normal ranges
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">A2 Tests and/or components with a limited set of textual results with or without normal ranges
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Example 1: positive/negative/indeterminate, resistant/intermediate/susceptibility
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Example 2: cytology/anatomic pathology
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Example 3: mutation type and location
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Example 4: organism name
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">A3 Tests with defined structure in Observation Result Segment OBX-3 through OBX-8 for the reporting of Culture Results and Antimicrobial Sensitivities (Need to resolve question mark in table regarding A3-Format)
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">A4 Semi-Structured or Unstructured
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Tests and/or components reported in a PDF or data blob
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">The group also discussed the possibility of attaching the In-Scope Tests list table as a stand-alone appendix; it is currently not locked down so that it is open for review.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Virginia Sturmfels shared some specific concerns expressed by members of the user community during the F2F meeting during the discussion of the In-Scope Tests list.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Creatinine with estimated GFR (eGFR) - will this enhance our list in some way? It was recommended as an addition by the user community at the F2F meeting. There is a separate LOINC term for eGFR and it was noted that it is a calculated result normally done within the LIS. Although examples of calculated test results are already included on the In-Scope Test list, it was suggested that it would not be a problem if eGFR is added in order to be sensitive to user community concerns.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Add Risk Assessment to Lipid Panel? There was a question as to whether there a LOINC term is defined for lipid risk assessment. One of the WG members looked it up and determined that there is only one specific LOINC term defined; 49062-3^Lipid risk factors [Finding]. We need to follow up with the person who suggested to include it to see if this meets the intended need before deciding to include it.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">All members seem comfortable with the Scope Test List as is, including the recommended addition.of eGFR.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">We need to follow up with Dr. James Harrison to see if he has some additional suggestions for incorporating anatomic pathology tests as part of the In-Scope Test list (Cindy Johns).
 * **<span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Position and Strategy for Use of SNOMED **
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Action for the group: please take an in-depth look at information in the Consensus document that was transposed from the Key Takeaways/Recommendations document developed at the F2F meeting.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Change “Recommend vs. require” in the intro paragraph? (“The workgroup recommends it as a required vocabulary”)
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Language to edit: HL7 “//likely// to be deprecated” vs. “will be”
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">For consideration: other CWE data types for genomics?
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">At this time, the Cystic Fibrosis test is the only genetics test on the list: can someone provide examples/sample answers?
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">We also want to determine if there are other vocabularies that genetics tests may use.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Riki and Bill to work on incorporating HL7 requirements into this document and building out a table by Thursday so it can be looked at next Tuesday
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Could incorporating this mean it could affect when we receive consensus?
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">It was decided at the F2F meeting that the content for HL7 does not have to get done by June 30; we may want to comment that we will be reviewing the tables from the HL7 perspective.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Follow up with Jim Case on pending questions (Riki Merrick)


 * **<span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Position and Strategy for UCUM **
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;"><span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">A ction for the group: please take an in-depth look at information in the Consensus document that was transposed from the Key Takeaways/Recommendations document developed at the F2F meeting.
 * <span style="color: black; font-family: 'Arial','sans-serif'; font-size: 13px;">Comment on third from last bullet - group not sure what it means. It was requested for a WG member to try to articulate this bullet a little more (referencing Canonical Names).

Next Meeting
 * Date:** 06/28/11
 * Time:** 10:00 AM- 11:00 AM
 * <span style="font-family: 'Arial','sans-serif'; font-size: 13px;">Dial In: ** <span style="font-family: 'Arial','sans-serif'; font-size: 13px;">1-408-600-3600 **<span style="font-family: 'Calibri','sans-serif'; font-size: 15px;">| Pass-code: **<span style="font-family: 'Arial','sans-serif'; font-size: 13px;"> 660 071 157

Reference Materials

 * 1) Consensus Statement
 * 2) In-Scope Test List

NOTE: Please see follow-up comments from Dr. Harrison under the Discussion tab in response to Action Item #9.

include component="page" wikiName="siframework" page="space.template.inc_contentleft_end"